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CLINICAL AND POPULATION STUDIES
COMP (Cartilage Oligomeric Matrix Protein) 
Neoepitope
A Novel Biomarker to Identify Symptomatic Carotid Stenosis
Joakim Sandstedt , Karin Vargmar , Kristina Björkman, Ulla Ruetschi , Göran Bergström , Lillemor Mattsson Hultén ,*  
Eva Skiöldebrand *
OBJECTIVE: COMP (cartilage oligomeric matrix protein) is abundantly expressed in the cardiovascular system, cartilage, and 
atherosclerotic plaques. We investigated if the total COMP (COMPtotal) and COMP neoepitope (COMPneo) with other 
cardiovascular markers and clinical parameters could identify symptomatic carotid stenosis.
APPROACH AND RESULTS: Blood samples were collected from patients with symptomatic carotid stenosis (stenosis, n=50), 
patients with stroke without carotid stenosis but small plaques (plaque, n=50), and control subjects (n=50). COMPtotal 
and COMPneo were measured using an ELISA. Ninety-two cardiovascular disease markers were measured by the Olink 
CVD kit. The presence of native COMP and COMPneo was determined by immunohistochemistry. The concentration 
of COMPneo was higher and COMPtotal was lower in the stenosis group. When the concentration was compared 
between the stenosis and control groups, IL-1ra (interleukin-1 receptor antagonist protein), IL6 (interleukin-6), REN 
(Renin), MMP1 (matrix metalloproteinase-1), TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand 
receptor 2), ITGB1BP2 (integrin beta 1 binding protein 2), and COMPneo were predictive of stenosis. Conversely, 
KLK6 (kallikrein-6), COMPtotal, NEMO (nuclear factor-kappa-B essential modulator), SRC (Proto-oncogene tyrosine-
protein kinase Src), SIRT2 (SIR2-like protein), CD40 (cluster of differentiation 40), TF (tissue factor), MP (myoglobin), 
and RAGE (receptor for advanced glycation end-products) were predictive of the control group. Model reproducibility 
was good with the receiver operating characteristic plot area under the curve being 0.86. When comparing the plaque 
group and stenosis group, COMPneo, GAL (galanin), and PTX3 (pentraxin-related protein PTX3) were predictive 
of stenosis. Model reproducibility was excellent (receiver operating characteristic plot area under the curve 0.92). 
COMPneo was detected in smooth muscle-, endothelial-, and foam-cells in carotid stenosis.
CONCLUSIONS: Degradation of COMP may be associated with atherosclerosis progression and generation of a specific COMP 
fragment—COMPneo. This may represent a novel biomarker that together with COMPtotal and other risk-markers could be 
used to identify symptomatic carotid stenosis.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: atherosclerosis ◼ biomarker ◼ carotid stenosis ◼ extracellular matrix proteins ◼ plasma ◼ stroke
Stroke is a significant cause of mortality and morbidity in industrialized countries, and it is the fifth leading cause of death in the United States.1 Most cases 
of stroke are of the ischemic type, where small or large 
vessel atherosclerosis accounts for the majority of cases. 
For large vessel atherosclerosis, the most common cause 
is carotid stenosis.1 A fast and accurate diagnosis of the 
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treatment. Current diagnosis is mostly based on clinical 
examination and neuroimaging, which may lack accuracy, 
is resource intensive and takes a significant amount of 
time. Thus, there is a great need for novel biomarkers to 
enhance current diagnostic procedures.
Atherosclerosis involves low-grade inflammation 
with proinflammatory cytokines during the early stages 
and disease progression,2 which leads to fragmenta-
tion of the extracellular matrix molecules. COMP 
(cartilage oligomeric matrix protein), also known as 
thrombospondin-5, was first described as a matrix 
protein in cartilage; however, it has subsequently also 
been found in the extracellular matrix of the arterial 
wall and in human atherosclerotic plaques.3–5
We recently discovered a unique COMP neoepitope 
(COMPneo) with cleavage site S154 (SGPTH), a highly 
conserved sequence that is identical across several 
species.6 The release of COMPneo in the synovial fluid 
and serum in horses with acute osteoarthritis indicates 
its role as a biomarker for cartilage degradation.7,8 We 
hypothesize that degradation of COMP in atherosclerotic 
plaques results in increased levels of COMPneo in the 
blood similar to what has been described in osteoarthritis 
and that the COMPneo may serve as a biomarker for 
advanced carotid atherosclerosis.
The aim of the present study was to investigate 
whether COMPneo is released in the blood of humans 
with and without symptomatic carotid atherosclerotic 
lesions. We also wanted to investigate whether the total 
COMP (COMPtotal) and COMPneo in combination 
with other biochemical and clinical risk markers could 
be used to create models for predicting symptomatic 
carotid stenosis. To elucidate the link between the levels 
of COMPneo in plasma and carotid atherosclerosis, the 
localization of native COMP and COMPneo were deter-
mined in samples from patients undergoing a carotid 
endarterectomy.
MATERIALS AND METHODS
Owing to the sensitive nature of the data collected for this 
study, this dataset cannot be made publicly available. However, 
access may be granted to qualified researchers trained in 
human subject confidentiality protocols by contacting the cor-
responding author.
All other supporting data are available within the article and 
in the Data Supplement. An extended material and methods 
section is available in the Data Supplement including infor-
mation regarding clinical chemistry analyses, COMPtotal and 
COMPneo analyses, protein expression profiling, immuno-
histochemistry, statistical methods used in Tables in the Data 
Supplement and sample size considerations.
Study Population
The study subjects were recruited from the Western Region 
Initiative to Gather Information on Atherosclerosis database9 
which includes patients with stroke at Sahlgrenska University 
Hospital and volunteers without previous stroke identified 
through official registers and invited for screening for carotid 
artery atherosclerosis (controls). From the Western Region 
Initiative to Gather Information on Atherosclerosis database, 
stratified and randomly selected groups with nonsignificant 
Nonstandard Abbreviations and Acronyms
AUC area under the curve
CD40 cluster of differentiation 40
COMP cartilage oligomeric matrix protein
COMPneo COMP neoepitope
COMPtotal total COMP
ECST European Carotid Surgery Trial
GAL galanin
IL-1ra  interleukin-1 receptor antagonist 
protein
IL-6 interleukin-6





OPLS-DA  orthogonal partial least square discrimi-
nant analysis
PCA principal component analysis
SRC  proto-oncogene tyrosine-protein kinase 
Src
PTX3 pentraxin-related protein PTX3
REN renin
ROC receiver operating characteristic
SIRT2 SIR2-like protein
TF tissue factor
TRAIL-R2  tumor necrosis factor-related apopto-
sis-inducing ligand receptor 2
Highlights
• Total cartilage oligomeric matrix protein 
(COMPtotal) and a COMP neoepitope together, 
with other cardiovascular markers and clinical 
parameters can be used to identify symptomatic 
carotid stenosis.
• IL-1ra (interleukin-1 receptor antagonist protein), 
IL-6 (interleukin-6), REN (renin), MMP1 (matrix 
metalloproteinase-1), TRAIL-R2 (tumor necrosis 
factor-related apoptosis-inducing ligand receptor), 
iITGB1BP2 (integrin beta 1 binding protein 2), and 
COMP neoepitope were predictive of stenosis.
• The degradation of native COMP may be associated 
with atherosclerosis progression with the genera-
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carotid lesions (plaque group, n=50) and controls (n=50) 
were included. From the Gothenburg Atheroma Study Group 
Biobank at the Sahlgrenska University Hospital,10 samples 
from symptomatic patients with high-grade carotid stenosis 
were available (stenosis group, n=50). High-grade carotid ste-
nosis was defined as ≥70% stenosis according to the ECST 
(European Carotid Surgery Trial) criteria. A detailed description 
of the diagnostic criteria has been published previously.9 There 
was no significant stenosis present in the other groups. The 
individuals included in the study were matched for age and sex. 
The study was approved by the Regional Ethical Review Board 
in Gothenburg. All the subjects provided written informed con-
sent before participation.
Blood samples from the patients were analyzed for 
COMPtotal and COMPneo, a panel of 92 proteins related to 
cardiovascular disease as well as some routine chemistry anal-
yses. Carotid endarterectomy samples for immunohistochemi-
cal analysis were obtained from the stenosis group (n=8).
Plasma Protein Quantification and 
Immunohistochemical Analysis
COMPneo was measured by an in-house ELISA.
The COMPneo ELISA was valid for plasma measurement 
with a detection limit of 125 ng/mL and an intraassay variation 
of 10.2% and an interassay variation of 23.8%. COMPtotal was 
measured by a commercial ELISA. Protein profiling with 92 pro-
teins was performed using the OLINK Proseek Multiplex CVD 
kit (catalog number 94200; Olink Bioscience, Uppsala, Sweden). 
Immunohistochemistry against COMPtotal and COMPneo was 
carried out on de-paraffinized serial sections from endarterec-
tomy samples after heat-induced epitope retrieval.
Statistical Analyses
Univariate analyses of COMPtotal, COMPneo, and ratio 
COMP neo/total on all study subjects were carried out by 
1-way ANOVA with post hoc analysis by Tukey’s multiple com-
parisons test using GraphPad Prism version 7.00 (GraphPad 
Software, La Jolla, CA). P≤0.05 was considered to be statisti-
cally significant.
Multivariate analyses were carried out using SIMCA v.15.0.2 
(Umetrics, Umeå, Sweden). Data were log transformed before 
statistical analysis. Variables were centered and scaled to unit 
variance. Goodness-of-fit was used to assess the explained 
variation (R2), while the reproducibility of the model was 
assessed by cross validation (Q2) as well as fitting the model 
on a validation dataset as described below. R2 and Q2 values 
of 1 represent a model that perfectly explains all the variations 
and that is perfectly reproducible.
Principal component analysis (PCA) was used to explore 
the segregation of patients based on all laboratory variables 
(chemistry-, protein-, and COMP-analyses) in an unbiased way. 
To further explore the predictive capacity of these variables, 
the dataset was randomly subdivided into training and valida-
tion datasets using a customized script in the R software (R 
Core Team [2018], https://www.R-project.org/). Of all cases, 
75% and 25% in each group were selected for the training and 
validation datasets, respectively. The training dataset was used 
to create predictive orthogonal partial least square discrimi-
nant analysis (OPLS-DA) models. The results are shown as a 
variable importance in the projection plot, predictive and plots 
of calculated regression coefficients. Variable importance in the 
projection plot, predictive gives an estimate of the importance 
of the different variables for the predictive model. A higher value 
indicates a higher degree of importance. Regression coeffi-
cients show the predictive direction of the different variables, 
for the group indicated on the y axis. Variables with coefficients 
>0 are positively associated with the indicated group, whereas 
variables with coefficients <0 are negatively associated. Error 
bars are displayed for coefficients at the 95% confidence level, 
estimated by a jack-knifing procedure. Coefficients where the 
error bars did not cross zero were considered most reliable.
To create submodels including the most important variables, 
only those variables that had a variable importance in the projec-
tion plot, predictive value >1, and with reliable regression coef-
ficients (ie, error bars that did not cross zero) were selected.
Predictive models were evaluated on the validation dataset. 
These results are presented as receiver operating characteristic 
(ROC) curves and misclassification tables, where observations 
were assigned to the nearest group. With the exception of Figure 
III in the Data Supplement, no threshold was used in the misclas-
sification tables. Fisher’s exact test results are included to show 
the probability of the observed table to occur by chance.
RESULTS
The clinical characteristics of the study subjects are pre-
sented in Table I in the Data Supplement. Notably, LDL 
(low-density lipoprotein) and total cholesterol were sig-
nificantly lower in both, the plaque and stenosis groups. 
As this most likely was the effect of more intensive 
lipid-lowering treatment in these groups (that may have 
been initiated due to the clinical event that was an inclu-
sion criterion for the present study), lipid analyses were 
excluded in subsequent multivariate analyses.
Plasma Levels of COMPtotal, COMPneo, and 
the COMPneo/COMPtotal Ratio
Plasma levels of COMPneo were significantly higher in 
the symptomatic patients with advanced carotid athero-
sclerotic lesions (stenosis) than in the control subjects 
(controls; Figure 1A). COMPneo levels were also signifi-
cantly higher in the stenosis group compared with patients 
with stroke with less advanced carotid atherosclerotic 
lesions (plaque). The levels of COMPtotal were lower in 
the patients with stenosis than in the control subjects (Fig-
ure 1B). There was also a significant difference between 
the plaque and stenosis groups. The COMPneo/COMP-
total ratio was higher in the plasma of patients with ste-
nosis than in the control or the plaque group (Figure 1C).
Multivariate Characterization of the Study 
Subjects Using Unsupervised PCA
An unsupervised PCA was used to explore whether a com-
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and cardiovascular disease markers would result in 
segregation of the different study groups (Figure 2). A 
PCA model with 4 significant components was obtained. 
While the first 2 PCA components did not reveal any 
clear segregation of the different study groups (Fig-
ure 2A), components 3 and 4 showed a clear segrega-
tion of the control and the stenosis groups (Figure 2B 
and 2C). Conversely, the control and the plaque groups 
seemed to overlap to a large extent. To further elucidate 
which aspects that PCA components 1 and 2 may rep-
resent, these were color coded against various clinical 
parameters (Figure I in the Data Supplement); however, 
no clear pattern was revealed.
A Predictive Model for the Stenosis Versus 
Control Group Using OPLS-DA Revealed 
Several Potential Biomarkers
For all the predictive models, the dataset was first ran-
domly subdivided into training and validation datasets. 
As the unsupervised PCA model showed the clearest 
segregation of the control and stenosis groups, these 2 
groups were included in an OPLS-DA predictive model 
to determine which parameters had the best predictive 
performance for carotid stenosis (Figure 3). Both clini-
cal and laboratory parameters were included. The OPLS-
DA model including all parameters (Figure 3A through 
3C) showed good predictive performance when applied 
to the validation dataset as determined by the ROC plot 
(area under the curve [AUC] 0.91) and misclassification 
table (Figure 3C). When a new OPLS-DA model with the 
most important variables was created (Figure 3D), only 
a slight decrease in predictive performance was noted 
when the model was applied to the validation dataset 
(Figure 3D, ROC plot and misclassification table, AUC 
0.86). Notably, the majority of the selected variables 
were significantly different between the control and ste-
nosis groups also when doing group-wise comparisons 
using standard parametric/nonparametric hypothesis 
tests and adjustment for multiple testing according to 
the Benjamini & Hochberg procedure (Table IIA and IIB 
in the Data Supplement).
A high concentration of IL-1ra (interleukin-1 recep-
tor antagonist protein), IL-6 (interleukin-6), REN (renin), 
MMP1 (matrix metalloproteinase-1), TRAIL-R2 (tumor 
necrosis factor-related apoptosis-inducing ligand recep-
tor), ITGB1BP2 (integrin beta 1 binding protein), and 
COMPneo in the plasma were found as predictive factors 
for the stenosis group when compared with the control 
group. Additional traditional risk factors such as smoking, 
smoking pack-years, diabetes, and hypertension were all 
predictive of stenosis.
Conversely, high concentrations of KLK6 (kallikrein-6), 
COMPtotal, NEMO (nuclear factor-kappa-B essen-
tial modulator), SRC (proto-oncogene tyrosine-protein 
kinase Src), SIRT2 (SIR2-like protein), CD40 (cluster of 
differentiation 40), TF (tissue factor), MB (myoglobin), 
and RAGE (receptor for advanced glycation end-prod-
ucts) were predictive of the control group (Figure 3D). 






































































Figure 1. COMP (cartilage oligomeric matrix protein) neo-
epitope (COMPneo) and total COMP (COMPtotal) plasma-
levels in the control, plaque, and stenosis groups.
Lines in figures indicate mean±SD. A, COMPneo levels. B, 
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laboratory parameters, showed similar predictive perfor-
mance when plotted on a ROC curve (Figure IIA and IIB 
in the Data Supplement, AUCs, 0.86 and 0.84, respec-
tively). However, the model with only laboratory param-
eters demonstrated the best classification performance 
when shown as a misclassification table.
A Predictive Model Using OPLS-DA Could 
Efficiently Identify Plaque and Stenosis 
Subjects
Since it would be of both clinical and scientific value to 
identify markers that are predictive of symptomatic carotid 
stenosis versus stroke without significant stenosis, a pre-
dictive OPLS-DA model was created between these 2 
groups (Figure 4). By including all the parameters (Figure 
4A through 4C), a model with very high predictive perfor-
mance was obtained, as determined by fitting the model to 
the validation dataset (Figure 4C, ROC-plot, and misclas-
sification table, AUC 0.96). However, a rather low Q2 value 
was observed by cross-validation (Figure 4C), which was 
probably a result of many of the variables being less impor-
tant and displaying a high degree of variation (ie, high error 
bars in the coefficients plot, Figure 4B).
When only selecting the most important and sig-
nificant variables, a model with only 7 variables was 
obtained (Figure 4D). One of these variables, TF had 
a coefficient close to 0 and thus did not contribute 
much to the model. Interestingly, this new model dis-
played a predictive performance very close to the full 
model with only a slight decrease in AUC (0.92) when 
fitted to the validation dataset (Figure 4D, ROC-Plot). 
Figure 2. Principal component analysis (PCA) of chemistry-, COMP (cartilage oligomeric matrix protein), and OLINK-analyses.
A model with 4 significant components was obtained. A, PCA score plot of the first 2 components. B, PCA score plot of components 3 and 
4, where a certain degree of clustering of the different groups are observed. The control and stenosis groups were most clearly separated, as 
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Figure 3. Comparison of control and symptomatic carotid stenosis (stenosis) groups.
A predictive orthogonal partial least square discriminant analysis (OPLS-DA) model was fitted, including both, laboratory and clinical variables. 
A, Shows variable importance plot predictive (VIPpred) for all variables. The red dotted line indicates the threshold for selecting variables for a 
submodel of the most important variables. B, Regression coefficients plots. Variables selected based on a VIPpred >1 are indicated by arrows. 
Variables that were considered significant based on error bars estimates are marked with asterisks. C, Validation of the model with cross-
validation on the training dataset (Q2 [cum], R2 [cum]) as well as fitting of the model on the validation dataset. For evaluating the classification 
performance based on the validation dataset, a receiver operating characteristic (ROC) plot and misclassification table are shown. D, New model 
calculated using only the most important variables. To the left, model fit determined by cross-validation on training dataset and a coefficients 
plot. To the right, results from fitting the new model on the validation dataset, shown by a ROC plot and misclassification table. 1=yes, 2=no, 
3=previous. AUC indicates area under the curve; CD40, cluster of differentiation 40; COMP, cartilage oligomeric matrix protein; f, female; 
FPR, false positive rate; IL-1ra, interleukin-1 receptor antagonist protein; IL6, interleukin-6; ITGB1BP2, integrin beta 1 binding protein 2; KLK6, 
kallikrein-6; m, male; MB, myoglobin; MMP1, matrix metalloproteinase-1; NEMO, nuclear factor-kappa-B essential modulator; RAGE, receptor for 
advanced glycation end-products; REN, rennin; SIRT2, SIR2-like protein; SRC, proto-oncogene tyrosine-protein kinase Src; TPR, true positive 
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Figure 4. Comparison of the plaque and stenosis groups.
A predictive orthogonal partial least square discriminant analysis (OPLS-DA) model was fitted, including both laboratory and clinical 
variables. A, Shows variable importance plot predictive (VIPpred) for all variables. Red dotted line indicates threshold for selecting variables 
for a submodel of the most important variables. B, Regression coefficients plots. Those variables selected based on a VIPpred >1 are 
indicated by arrows. Variables that were considered significant based on error bars estimates are marked with asterisks. C, Validation of 
the model with cross-validation on the training dataset (Q2 [cum], R2 [cum]) as well as fitting of the model on the validation dataset. For 
evaluating classification performance based on the validation dataset, a receiver operating characteristic (ROC) plot and misclassification 
table are shown. D, New model calculated using only the most important variables. To the left, model fit determined by cross-validation on 
training dataset and a coefficients plot. To the right, results from fitting the new model on the validation dataset shown as ROC plot and 
misclassification table. 1=yes, 2=no, 3=previous. AUC indicates area under the curve; CD40, cluster of differentiation 40; COMP, cartilage 
oligomeric matrix protein; f, female; FPR, false positive rate; GAL, galanin; KLK6, kallikrein-6; m, male; PTX3, pentraxin-related protein PTX3; TF, 
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Additionally, cross-validation, as expected, showed a 
much higher degree of reproducibility as determined 
by a higher Q2 value. In the reduced model, smoking 
pack-years and the following laboratory parameters 
were predictive for stenosis; a high concentration 
of COMPneo, GAL (galanin), and PTX3 (pentraxin-
related protein PTX3) in plasma. Predictive parameters 
for the plaque group were increased concentrations 
of CD40 and KLK6 (Figure 4D). When doing group-
wise comparisons using standard parametric/nonpara-
metric hypothesis tests (Table IIIA and IIIB in the Data 
Supplement), COMPneo and KLK6 were significantly 
different between the plaque and stenosis groups after 
adjustment for multiple testing.
Importantly, when fitting an OPLS-DA model using 
only clinical parameters, poor predictive performance 
was observed compared with an OPLS-DA model with 
only laboratory parameters (Figure IIC and IID in the 
Data Supplement).
To investigate the predictive performance of a model 
including all 3 study groups, an OPLS-DA model was 
created for this scenario (Figure III in the Data Supple-
ment). As expected from the PCA analysis (Figure 1), 
the control and stenosis groups showed high AUCs in 
the ROC plot (0.81–0.90) when fitted to the validation 
dataset, whereas the plaque group was the most dif-
ficult to classify correctly and displayed a lower AUC in 
the ROC plot (0.70).
COMPneo Staining Was Associated With 
Atherosclerotic Lesions
COMPneo and native COMP staining largely fol-
lowed the same pattern of immunoreactivity, sug-
gesting that the polyclonal antibody directed against 
native COMP also recognizes its cleaved fragments. 
Immunohistochemical analysis revealed a predomi-
nantly intracellular localization in and around the ath-
erosclerotic lesions.
Smooth muscle cell staining was localized adja-
cent to atherosclerotic plaques, whereas cells further 
from the lesions were unstained (Figure 5A and 5B). 
Positive staining in smooth muscle cells for COMP-
neo, occurred both intracytoplasmatically and intra-
nuclearly (Figure 5C and 5D). A population of these 
positive cells had a morphology suggestive of a motile 
phenotype with irregular shape and protrusions. Fur-
thermore, foam cells had a consistent cytoplasmatic 
staining of both native COMP and COMPneo; how-
ever, consistent intranuclear staining was only visible 
with COMPneo (Figure IVA and IVB in the Data Sup-
plement). The endothelial cells and leukocytes showed 
a more variable staining pattern (Figure IVC and IVD in 
the Data Supplement). A summary of the immunohis-
tochemical results is presented in Table IV in the Data 
Supplement.
DISCUSSION
The present study is the first to show that plasma lev-
els of COMPtotal and a unique COMPneo in patients 
with symptomatic carotid stenosis are significantly dif-
ferent when compared with both, patients with stroke 
with milder carotid lesions and to control subjects. The 
stenosis group displayed the highest concentrations of 
COMPneo and lowest concentration of COMPtotal. Fur-
thermore, COMPtotal and COMPneo together with other 
cardiovascular risk markers could predict the presence 
of carotid stenosis with high accuracy. Finally, COMPneo 
was found in human carotid atherosclerotic lesions, indi-
cating its potential functional role in the progression of 
atherosclerosis.
COMP has previously been shown to be involved in 
atherosclerosis progression3,11 as well as the progression 
of osteoarthritis.12 The low-grade inflammation present in 
atherosclerosis and osteoarthritis2,13 leads to fragmenta-
tion of extracellular matrix molecules and the formation 
and release of unique neoepitopes. In the present study, 
increased levels of COMPneo were detected in patients 
with carotid stenosis, supporting an increased degrada-
tion of COMP in severe atherosclerotic disease.
When the stenosis group was compared with the 
control subjects in the multivariate analysis, several 
clinical background factors were found to be highly 
predictive for the stenosis group. All these are previ-
ously well-known risk factors for the development of 
atherosclerosis and carotid stenosis.14 Interestingly, 
blood pressure was not found to be a discriminating 
Figure 5. Immunoreactivity against native COMP (cartilage 
oligomeric matrix protein) and neoepitopes in human carotid 
plaques.
*Intralesional plaques. Arrows toward cells with smooth muscle cell 
(SMC) morphology. Overview of the lesion in the common carotid 
artery (×100), native COMP (A), and neoepitope (B). Staining of 
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variable. This apparent paradoxical finding was most 
likely because these patients received sufficient treat-
ment for hypertension.
When patients with stroke were compared with 
patients with symptomatic stenosis, only smoking pack-
years was found to be a clear discriminating variable 
among the clinical background variables. This sug-
gested that while other clinical variables are important 
for the development of atherosclerotic disease, smoking 
exposure has the strongest association to large ves-
sel atherosclerotic disease. This is in accordance with 
a population-based study where current smoking was 
identified as the strongest risk factor for carotid artery 
atherosclerosis.15 Our study further extends these results 
by showing that cumulative smoking exposure rather 
than the presence of smoking is most important for pre-
dicting carotid stenosis.
Several of the predictive factors for the stenosis 
group when compared with those of controls (ie, IL-1ra, 
IL-6, MMP1, TRAIL-R2, ITGB1BP2, REN, and COMP-
neo) have previously been associated with inflammation. 
Elevated levels of proinflammatory cytokines such as 
IL-6 are associated with all stages of atherosclerosis.16 
MMP1 is also upregulated by inflammation and contrib-
utes to atherosclerosis progression by tissue remodeling 
and paracrine effects.17 TRAIL-R2 belongs to the tumor 
necrosis factor receptor superfamily and participates in 
the regulation of the adaptive immune response.18
The finding of IL-1 receptor antagonist protein as a 
predictive factor for stenosis may seem paradoxical, as 
this is a natural inhibitor of the proinflammatory cytokine 
IL-1 and has been linked to reduced atherosclerosis 
in animal models.19 This could be attributed to the fact 
that IL-1 receptor antagonist protein is upregulated as a 
negative feedback mechanism by concurrent high levels 
of IL-1. Unfortunately, IL-1 was not included in the Olink 
cardiovascular disease panel, which precludes us from 
evaluating the balance between IL-1 and the IL-1 recep-
tor antagonist protein.
In summary, most predictive factors for carotid ste-
nosis were associated with the immune response, 
inflammation, and extracellular matrix degradation, 
supporting the role of systemic inflammation in chronic 
atherosclerosis.
Conversely, KLK6, COMPtotal, NEMO, SRC, SIRT2, 
CD40, TF, MB, and RAGE were parameters predictive of 
the control group.
Both KLK6 and SIRT2 have previously been shown 
to have prosurvival or anti-apoptotic effects. SIRT2 
has been linked to decreased atherosclerotic plaque,20 
whereas KLK6 to our knowledge has not been previ-
ously described in the context of atherosclerosis.
CD40 is a receptor expressed by macrophages, which 
also exists in a soluble form. Soluble CD40 has been 
reported to limit CD40-CD40 ligand interaction and con-
fer protection against atherosclerosis.21 Data on soluble 
CD40 in cardiovascular disease are limited. However, 
one study, in contrast to our results, reported increased 
levels in coronary heart disease.21
When the stenosis and plaque groups were com-
pared, fewer predictive markers were found. The reason 
for this may be that the stenosis and plaque groups had 
more similar comorbidities, including atherosclerotic dis-
ease in other locations in the arterial tree, compared with 
the stenosis and control groups. With the exception of 
smoking pack-years, none of the clinical background fac-
tors showed high predictive performance, underlining the 
need for biomarkers to separate the stenosis and plaque 
groups. The plasma concentration of COMPneo, GAL, 
and PTX3 were predictive factors for stenosis.
COMPneo was found to be the most important pre-
dictive factor when the stenosis group was compared 
with the plaque group. Notably, it was also found to be 
a predictive factor for stenosis when the stenosis group 
was compared with the control group—indicating that it 
may be the most clearly associated marker with athero-
sclerotic disease severity in the present study.
GAL is involved in the regulation of energy homeo-
stasis. In a mouse model, it was shown that increased 
levels of GAL resulted in a phenotype similar to meta-
bolic syndrome with insulin resistance and a lipid profile 
with high triglyceride levels.22 To our knowledge, it has 
not been previously associated with atherosclerosis or 
carotid stenosis.
PTX3 is an acute phase protein belonging to the same 
family as C-reactive protein. PTX3 has previously been 
associated with atherosclerotic disease in a number of 
studies, including one on carotid plaques where high lev-
els of PTX3 were predictive of plaque vulnerability.23
CD40 and KLK6 were predictive for stroke without 
carotid stenosis (plaque group). Notably, these markers 
were also predictive of the control group when compared 
to the stenosis group and are discussed in further depth 
in this section. This could be interpreted as these mark-
ers being most clearly negatively correlated with the 
severity of atherosclerotic disease.
The location of native COMP and the COMPneo in 
atherosclerotic artery tissue was investigated in endar-
terectomy samples. Native COMP has previously been 
detected in the medial layer of normal internal arteries, 
in vascular smooth muscle cells with normal contractile 
phenotype, and in the extracellular matrix of arteries with 
intimal thickening.3 The presence of COMP degradation 
products has not been previously investigated in athero-
sclerotic lesions. In our study, there was a clear overlap 
between the immunohistochemistry staining for native 
COMP and COMPneo in the atherosclerotic lesions. 
An explanation could be that the polyclonal antibody 
against the native form of COMP recognizes the intact 
molecule as well as various COMP fragments while the 
neoepitope antibody is specific to the cleavage site.8 




 http://ahajournals.org by on June 10, 2021
Sandstedt et al COMP Neoepitope Levels in Atherosclerosis
Arterioscler Thromb Vasc Biol. 2021;41:1218–1228. DOI: 10.1161/ATVBAHA.120.314720 March 2021  1227
CLINICAL AND POPULATION  
STUDIES - AL
is degraded in advanced atherosclerotic lesions. Inter-
estingly, we detected cells with the motile morphology 
of smooth muscle cells that stained positive for COMP-
neo in the cytoplasm and in the nucleus. This observa-
tion suggested that signaling conveyed by neoepitopes 
may have a role in de-differentiation of vascular smooth 
muscle cells.
Some limitations of the present study should be 
acknowledged. The cases with symptomatic carotid ste-
nosis were included from a different patient cohort com-
pared with the plaque group. This resulted in slightly 
different inclusion criteria, where the symptomatic carotid 
stenosis cohort either suffered from stroke, transient isch-
emic attack, or amaurosis fugax, whereas all the subjects 
in the plaque group suffered from stroke. Although we 
cannot exclude its effect on the results, when the OPLS-
DA discriminatory model was recalculated on only stroke 
cases, the pattern of variables was similar to the original 
model. Furthermore, when the model with only the most 
important variables presented in the study was evaluated 
on only stroke cases in the validation dataset, the predic-
tive performance was similar to when all the cases were 
included (AUC 0.97, data not shown). Another general 
limitation of the study was that blood samples were not 
drawn at the time of the clinical event, but rather when 
patients were included in the study. In most cases, this was 
within a few days after the clinical event; however, in some 
cases, this happened up to a few weeks after the event. 
Finally, the study had a small sample size and the results 
thus need to be confirmed in a larger patient cohort.
In summary, our data suggest that degradation of 
COMP may be associated with inflammation in athero-
sclerosis progression with the generation of a specific 
COMP fragment. In blood, this COMPneo was found to 
represent a novel biomarker that, together with additional 
biomarkers and risk factors, efficiently identified patients 
with symptomatic carotid stenosis. Our results could 
potentially be used to develop a screening tool for patients 
with stroke with the highest risk of carotid stenosis for 
early carotid artery screening to reduce time delay to end-
arterectomy surgery. However, a further validation study 
on a larger cohort is necessary. There is also a need for 
further mechanistic studies to elucidate the role of COMP 
and COMP degradation products including the COMPneo 
in the progression of atherosclerotic disease.
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